Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
ApexOnco Front Page
Recent articles
And the company believes it won’t need to carry out another trial.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
The company will start three phase 3 trials of its G12D project this year.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
But the company still has a lot to prove with ERAS-0015.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
